Insmed: Revenue Nearly Quadrupled, but Losses and Valuation Keep It a Hold

Insmed Incorporated grew trailing-twelve-month revenue by 296.1%, one of the fastest top-line expansions in our coverage, and the Growth pillar of our scoring model reflects that at 90/100. Even so, the company still posted a net margin of -76.9%, negative free cash flow of $572M, and trades at nearly 36 times book value. This Insmed Incorporated stock analysis walks through how a genuine commercial inflection sits alongside a Quality score of 33/100 and an Opportunity score of 7/100, leaving our model with a Hold signal and a Recommendation score of 43/100.

What Is Happening With the Stock Price

At $124.89, Insmed trades near the middle of its two-year range of $65.08 to $207.77, roughly 42% of the way up that band and about 40% below the two-year high. The shares have retraced a meaningful part of an earlier advance rather than pressing toward new highs. Market capitalisation is $27.27B, about 24 times trailing revenue of $1.1B. That is a demanding multiple, and it signals the market is already crediting Insmed for several more years of rapid growth. For a company without positive earnings, the stock tends to move on clinical and commercial updates rather than on valuation math.

Quality: Is This a Financially Sound Business?

Gross margin is strong at 83.5%, typical of a branded drug business, but the rest of the profitability picture is still deep in the red. Operating margin is -23.8%, net margin is -76.9%, return on equity is -87.2%, and return on assets is -22.2%. Free cash flow was -$572M over the trailing twelve months, an FCF yield of -2.1%, so the company is funding its growth from its balance sheet rather than from operations. Liquidity is adequate, with a current ratio of 3.72 and a quick ratio of 3.13, and debt-to-equity of 0.98 is moderate for a business at this stage. The Quality score of 33/100 reflects a high-margin product line offset by large losses and cash burn.

Growth: Does This Company Have Real Upside?

This is where Insmed stands out. Trailing-twelve-month revenue rose 296.1%, well ahead of the five-year CAGR of 35.2%, a pattern consistent with a newer product moving through its launch phase and pulling the recent growth rate above the longer-run average. Earnings growth is not meaningful yet because the company is unprofitable. EV/Revenue of 23.87 is high, and EV/EBITDA of -34.16 is negative because EBITDA itself is negative, so that multiple carries no signal here. The Growth score of 90/100 is the clear strength in this Insmed Incorporated stock analysis, though a rate this high is unlikely to hold once the comparison base rebuilds.

Opportunity: Is Now a Good Time to Enter?

Opportunity scores just 7/100, the lowest pillar by a wide margin. There is no P/E because earnings are negative, and price-to-book of 35.99 is extremely high, so the valuation offers little cushion if growth slows or a setback occurs. The one point in a buyer’s favour on timing is that the stock sits near the middle of its two-year range rather than at the top, so the entry point is less stretched on price than it was near the high. Even so, the model reads the overall valuation as expensive.

Insmed Incorporated Stock Analysis: The Bottom Line

To close this Insmed Incorporated stock analysis, the bull case is straightforward: an 83.5% gross margin, revenue up 296.1% over the past year, a 35.2% five-year growth rate, and a solid liquidity position. The bear case is equally clear: a -76.9% net margin, -$572M of free cash flow, price-to-book near 36, and a valuation that assumes years of continued rapid growth. The main risk is that any slowdown in the product ramp, competitive pressure, or a clinical disappointment would hit a stock priced for near-perfect execution; the offsetting factor is that the growth trajectory, if sustained, could grow the company into part of that valuation. Our scoring model balances these to a Hold signal, with Quality at 33, Growth at 90, and Opportunity at 7 out of 100. That signal is a transparent, data-driven starting point for research, not personalised advice to transact.